Reference
Park JH, et al. Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors. Anticancer Research 42 : 6091-6098, No. 12, Dec 2022. Available from: URL: http://doi.org/10.21873/anticanres.16121
Rights and permissions
About this article
Cite this article
Irinotecan/temozolomide. Reactions Weekly 1953, 226 (2023). https://doi.org/10.1007/s40278-023-37661-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-37661-0